CHICAGO & VIENNA--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a global clinical evaluation program spanning three continents and five internationally recognized institutions to assess StarGuide™ GX,i its next-generation digital 4D SPECT/CT system. Participating institutions include Hadassah Medical Center in Israel; Mayo Clinic in the United States; Oncopole Claudius Regaud – Institut Universitaire du Cancer de Toulouse in France; Peking University First Hospital in China; and

SAN FRANCISCO--(BUSINESS WIRE)--Radical Numerics, an AI research lab building general biological intelligence, today launched Omnii-1, a biological AI model that learns across DNA, RNA, proteins and other molecular data. Researchers used Omnii to design a bacteriophage and administered it to a patient with a drug-resistant bacterial infection, marking the first AI-designed phage given to a human patient. Omnii-1 is a genome language model built on the same AI technology behind large language mo

CHARLOTTE, N.C.--(BUSINESS WIRE)--Enpro (NYSE: NPO) to release financial results for Q3 2026 on Tues, Nov 3rd, at 6:30 am ET followed by a conference call at 8:30 am ET.

SAN FRANCISCO--(BUSINESS WIRE)--Electric Plant Company today emerged from stealth with $11.2 million in seed funding and the debut of Bombadil, the first AI foundation model for plant electrophysiology. Trained on more than 4 million hours of recordings across 100 species and a range of environments, Bombadil is the most species-diverse foundation model ever built on biological signals. It reads a plant's health state directly from the plant's own electrical activity, rather than inferring it f

ABU DHABI, United Arab Emirates--(BUSINESS WIRE)--Eight Sleep, the global leader in sleep technology, today announced that its smart bed technology has been approved as a medical device in Abu Dhabi to support the diagnosis of obstructive sleep apnea. Announced at the Abu Dhabi Future Health Summit 2026, the approval follows a Health Technology Assessment (HTA) by the Department of Health – Abu Dhabi (DoH). The approval enables physicians to prescribe the Eight Sleep smart bed system to adults

NEWTON, Mass.--(BUSINESS WIRE)--Axena Health, Inc. (Axena Health), a women’s health company redefining the standard of care for pelvic health conditions through clinically proven, non-invasive treatments, today announced it has been named a finalist for the Digital Health Hub Foundation – Digital Health & AI Awards 2026 at HLTH. Selected from a pool of more than 1,300 participating companies across all tracks and categories, Axena Health is recognized in the Best in Class Track for Women’s

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that the Company and its U.S. subsidiary eyonis Inc. will present eyonis® LCS at the 50

WASHINGTON--(BUSINESS WIRE)-- #Aging--Fasano Longevity Conference to Cover Politics, Artificial Intelligence, and Life Expectancy Research

WASHINGTON--(BUSINESS WIRE)-- #CleaningIsCaring--Cold and flu season is taking a major toll on Americans’ daily lives. A new survey from the American Cleaning Institute (ACI) and the American Academy of Family Physicians (AAFP) finds that 91% of respondents say these illnesses cause significant disruption. Parents report feeling the disruption across nearly every part of family life, including:61% experiencing missed work or school,55% reporting impacts to after-school activities, and52% dealing with disrupted slee

PALO ALTO, Calif. & LONDON--(BUSINESS WIRE)--Becaris Publishing, an independent scholarly publisher dedicated to advancing real-world evidence (RWE) and health economics and outcomes research (HEOR), today announced it is conducting a first-of-its-kind 12-month independent study to evaluate the clinical quality and methodological rigor of Alexandria. Created by Atropos Health, Alexandria is the world’s largest evidence library. No scholarly publisher has ever undertaken a peer-review evaluation

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--A new research survey of 74 U.S. life sciences leaders finds direct-to-patient's mission-critical urgency is rising.

HOUSTON--(BUSINESS WIRE)--HPE Spaceborne Computer plans to run AI and HPC benchmarks on the Moon, laying the groundwork for future exploration and the emerging lunar economy.

ABU DHABI, United Arab Emirates--(BUSINESS WIRE)--Future Health – A Global Initiative by Abu Dhabi today premiered a documentary film about the inaugural Future Health Impact Challenge during the first day of the Abu Dhabi Future Health Summit. The film’s global launch, alongside the announcement of the second Challenge connects the Challenge’s initial results with its next phase with Expressions of Interest now open for the second edition. Delivered in collaboration with MIT Solve, the inaugur

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Mad

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI) will highlight its latest research insights through more than 85 abstracts and presentations at ESMO.

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Savillex, LLC ("Savillex"), a leading provider of high-purity fluid handling solutions for life science and laboratory applications worldwide, today announced that it has completed its acquisition of Entegris, Inc.'s Life Sciences Fluid Management business. The acquired portfolio includes bioprocessing and pharmaceutical manufacturing solutions, including Aramus™ and PE bags, single-use assemblies, and components used across discovery, clinical, and commerc

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, a leader in remote physiologic monitoring (also known as remote patient monitoring or RPM) solutions, today announced two new offerings for qualifying healthcare providers: free patient onboarding and engagement services to improve device use and adherence through its signature SmartTouch® program, and lower monthly service fees. Together, they are designed to help practices start, scale, and sustain RPM programs at a time when administrative demands a

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced that four research abstracts will be presented as e-posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The research examines how cancer treatments are used in everyday practice, how patient outcomes vary, and where additional evidence could help inform care across the United States, Germany, Japan, and the United Kingdom. Spanning colorectal, lung, and prostate cancer,

BOSTON--(BUSINESS WIRE)--Sware, Inc., the company behind the AI-powered validation platform Res_Q and a provider of GxP compliance solutions, today announced the appointment of Erin Wright as Chief Product Officer. Wright will lead product strategy across Sware’s portfolio as the company expands AI-powered validation across life sciences and other regulated industries. Wright has 20+ years in B2B Life Sciences SaaS organizations, most notably spent 14 years at MasterControl, advancing from cust

WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III CROSSING trial showed that AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of histologic remission and the frequency and severity of dysphagia (difficulty swallowing) in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis (EoE), despite continued treatment with background medicat

SAN JOSE, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)-- #NGS--Takara Bio and SPT Labtech partner to deliver verified firefly workflows, bringing automation-ready NGS library preparation to more labs.

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced a new research collaboration with the Medical University of South Carolina (MUSC). The collaboration will leverage BostonGene’s biologically grounded AI platform to model longitudinal immune system dynamics and identify the biological mechanisms associated with treatment response, resistance, toxicity, and durability in patients receiving an innovative CAR-T cell therapy.

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Beauty--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by the Niagen® Skincare Innovation Lab. The inaugural product in this new category is Niagen NanoCloud™, the first dermatologist-tested topical product powered by Niagen® (patented nicotinamide riboside, or NR

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat to Host Second Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, November 3, 2026 at 4:30 p.m. Eastern Time

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, announced new data at an investor event in New York City from the ARC-20 platform study, which is evaluating casdatifan, an investigational next-generation HIF-2α inhibitor, alone or in combination, as a first-, second- and late-line treatment for clear c

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published

BRIDGEWATER, N.J.--(BUSINESS WIRE)--EVOXAC (cevimeline HCl) Oral Solution FDA Approval

COLUMBUS, Ohio--(BUSINESS WIRE)--EdgeConneX®, a pioneer in global Build-to-Suit and Build-to-Density digital infrastructure solutions, today announced a multi-year investment supporting two complementary Hello World initiatives to expand computer science and AI literacy for Ohio students. Recently launched, the initiatives have already reached approximately 10,000 students across 11 school districts. The investment comes as Ohio expands access to computer science through the state-established C

PARIS & BOSTON--(BUSINESS WIRE)-- #BYN002--Bionyra Pharma Announces Positive Interim Phase 1 Results for BYN-002, a Long-Acting Anti-TL1A Antibody

SAN DIEGO--(BUSINESS WIRE)--Sinopia Biosciences, Inc., a biotechnology company leveraging multi-omics data, high-throughput screening, and artificial intelligence to identify and develop first-in-class therapies for diseases with significant unmet need, today announced it has been awarded a $2.5 million Small Business Innovation Research (SBIR) Phase II grant (R44GM154585) from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH). The award

SAN FRANCISCO--(BUSINESS WIRE)-- #FSHD--Epicrispr Biotechnologies Appoints Enoch Kariuki, PharmD, to Board of Directors

CHICAGO--(BUSINESS WIRE)--IMIO, the pioneering manufacturer of a new generation of dependable agricultural biologicals, has raised $12 million to help farmers transform soil performance and protect profitability. The round was led by Sofinnova Partners with additional backing from Chipotle’s Cultivate Next venture fund, Starshot Capital, Grow Together Salinas, Earth Foundry and Serra Ventures. The investment will be used to support the development of the company’s new lab and biomanufacturing op

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, pleas

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced that its Revvity Signals Software business is launching the Signals LabGistics™ solution, an AI-first, scientific workflow orchestration solution designed to connect and coordinate processes, workflows, and tasks from discovery to manufacturing. The Signals LabGistics offering uses AI-powered workflow design to translate natural-language descriptions and standard operating procedures into coordinated scientific workflows. As

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using the same instrument-free workflow, researchers can profile up to 2.5 times as many cells across up to twice as many samples within their existing budget, or run the same experiment at roughly half the overal

PARAMUS, N.J.--(BUSINESS WIRE)--Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company employing standard-of-care therapies with proprietary delivery technologies, announced today that Chairman and Chief Executive Officer Pedro Lichtinger will participate in the Longwood Healthcare Leaders Boston CEO meeting, taking place November 2-3 at the Mandarin Oriental in Boston. Lichtinger will join fellow biopharmaceutical leaders for a panel discussion on building global biophar

SANTA CLARA, Calif.--(BUSINESS WIRE)--Next-generation IVL catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease.

BOCA RATON, Fla.--(BUSINESS WIRE)--Algia Pharma, LLC (“Algia”) today announced the successful completion of its Investigational New Drug (IND)-enabling preclinical toxicology study for AlgiaPak®. AlgiaPak is a hospital-grade multimodal pain regimen designed to treat all mild-to-moderate acute pain as effectively as opioids, without exposing patients to the risk of opioid addiction. Results from the study, conducted in full compliance with Good Laboratory Practice (GLP) standards, demonstrated t

PARSONS, Kan.--(BUSINESS WIRE)--Deep Fission, Inc. (Nasdaq: FISN) today announced a Master Energy Purchase Agreement with the Great Plains Development Authority (GPDA), a quasi-municipal entity that owns the Great Plains Industrial Park in Parsons, Kansas. It converts the parties’ December 2025 letter of intent into a definitive contract for a commercial project at the site of Deep Fission’s Department of Energy (DOE) pilot. The agreement binds Deep Fission to pursue the project and to supply p

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will present data from its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany. New preclinical data to be featured are aimed at addressing two import

WOBURN, Mass.--(BUSINESS WIRE)-- #Oralmedicines--Orogen Therapeutics announces selection of two development candidates for immune diseases.

PARIS--(BUSINESS WIRE)-- #biotech--Single-cell profiling at diagnosis can identify which patients with an aggressive form of ovarian cancer are likely to experience treatment failure.

TEL AVIV, Israel--(BUSINESS WIRE)--Nano24 Ltd., a privately held, clinical-stage biotechnology company developing engineered exosome therapeutics, today announced positive results from its randomized, double-blind, placebo-controlled Phase 2b trial of inhaled EXO-CD24 in patients with acute respiratory distress syndrome (ARDS). The data are being presented today by Shiran Shapira, Ph.D., Co-Founder and Chief Scientific and Technology Officer (CSO/CTO) of Nano24, in the “Top Late-Breaking Abstra

ST. LOUIS--(BUSINESS WIRE)--Vionic, a lead brand in the Caleres (NYSE: CAL) portfolio, is introducing Weightless Walking with the debut of Hummingbird, the lightest walking shoe the brand has ever made. Weighing approximately seven ounces, Hummingbird features VioFeather™, a new innovation engineered specifically around the biomechanics of walking to create an exceptionally lightweight experience without compromising Vionic’s defining support and comfort. The innovation starts with a simple pre

NEW YORK--(BUSINESS WIRE)--Evercore ISI ranked No. 1 among all firms on a weighted basis in the analyst rankings of the 2026 Extel (previously Institutional Investor) All-America Research Team survey, marking its fifth consecutive year in the top position. The weighted ranking assigns greater value to higher placements, with first-place rankings contributing more than second- and third-place rankings. Evercore research analysts were recognized as Top 3 or Runner-Up in 40 categories. The firm ea

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. The company celebrated the openi

VOORHEES, N.J.--(BUSINESS WIRE)--New Jersey Urology advances care across the region opening new outpatient centers led by three nationally recognized interventional radiologists

PITTSBURGH--(BUSINESS WIRE)--Life Science Connect Acquires BrevisRefero, Expanding Biopharma Outsourcing Capabilities with RFP>Navigator®

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report. These results identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing. Real-Time Variant Tracker includes variants with established clinical significance, includi

LOS ANGELES--(BUSINESS WIRE)--Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have uncovered an immune pathway that may contribute to radiation-related lung damage and have identified a potential strategy to block it. Published today in Nature Communications, the insights from the preclinical study could lead to new treatments that prevent radiation from harming healthy lung tissue and improve patients’ quality of li

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma announces conference call for third quarter 2026 business and financial update

PHILADELPHIA--(BUSINESS WIRE)-- #AZUR--Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

CARLSBAD, Calif--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2026 financial results on October 29, 2026, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET.WebcastTo access the live webcast, please use this link or visit the Events & Presentations section of ATEC’s Investor Relations web

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights five areas: Scaling genomic interpretation with AI and machine learning: A GeneDx

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The Company also highlighted the publication of an independent, investigator-led analysis of percutaneous hepatic perfusion (PHP) w

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Revea

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer (NSCLC). The panel achieved greater than 80% sensitivity across all 12 biomarkers assessed, with sensitivity exceeding 90% for several biomarkers, supporting its potential to identify patients who may need confirmatory biomarker testing. Results from the study will be presented at the European Society for

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, a leader in remote physiologic monitoring (also known as remote patient monitoring or RPM) solutions, today announced two new offerings for qualifying healthcare providers: free patient onboarding and engagement services to improve device use and adherence through its signature SmartTouch® program, and lower monthly service fees. Together, they are designed to help practices start, scale, and sustain RPM programs at a time when administrative demands a

BOCA RATON, Fla.--(BUSINESS WIRE)--Algia Pharma, LLC (“Algia”) today announced the successful completion of its Investigational New Drug (IND)-enabling preclinical toxicology study for AlgiaPak®. AlgiaPak is a hospital-grade multimodal pain regimen designed to treat all mild-to-moderate acute pain as effectively as opioids, without exposing patients to the risk of opioid addiction. Results from the study, conducted in full compliance with Good Laboratory Practice (GLP) standards, demonstrated t

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The study (SMT112-216 / AK112-216 / NCT07877194) is being conducted in collaboration with Summit’s partner, Akeso Inc. SMT

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for autoimmunity and cancer, will deliver an oral presentation at the 2026 American College of Rheumatology (ACR) Convergence, taking place November 6-11 in Orlando, Florida. Palleon's presentation will take place on Wednesday, November 11. Details of Palleon's Presentation: American College of Rheumatology (ACR) Convergence Title: Rapid and deep clinical responses to H

MIAMI--(BUSINESS WIRE)-- #COVID19--AIDS Healthcare Foundation (AHF) welcomes the United Nations General Assembly’s adoption of the Political Declaration on Pandemic Prevention, Preparedness, and Response, with 153 countries voting in favor and only three against. AHF urges governments to turn this strong affirmation of international cooperation into concrete commitments that protect people from future pandemics. “Effective coordination on pandemic prevention, preparedness, and response is of utmost import

NEW YORK--(BUSINESS WIRE)--Fortell today announced it is expanding access to its prescription AI hearing aids across more than 30 states through new clinics and Fortell Anywhere, its remote audiology service.Fortell’s custom AI chips use spatial cues to separate speech from competing sounds in real time, directly on the device, and without a perceptible lag. By isolating voices and reducing background noise before amplification, Fortell helps people follow conversations in restaurants, crowded r

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Reservoir today launched a personal cell preservation service that lets adults preserve their own immune cells through a standard blood draw. Reservoir is available today through partner clinics in San Francisco, Boston, Los Angeles, and New York City, with in-home appointments launching in select markets. Sign up at withreservoir.com to be matched with a nearby appointment or to receive updates when Reservoir comes to your city. To see Reservoir in action, go

LAS VEGAS & PANAMA CITY--(BUSINESS WIRE)-- #AABB--Auragens, an international regenerative medicine and research institute, today announced that its research paper, "Molecular Dynamics Simulation of SOD3 and CXCR4 Proteins in Engineered Mesenchymal Stem Cells for Radiation Countermeasure Therapeutics," has been formally accepted for presentation at the 2027 American Institute of Aeronautics and Astronautics (AIAA) SciTech Forum, taking place January 11–15, 2027, in Orlando, Florida.The paper, authored by

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to

MIAMI & BALTIMORE--(BUSINESS WIRE)-- #ClinicalAI--OpenEvidence and Johns Hopkins Medicine are collaborating to design medical education and clinical care for the AI era, with patients at the center.

NEW CASTLE, Del. & SAN ANTONIO--(BUSINESS WIRE)--IgniteData, a leader in intelligent clinical trial data automation, and RealTime eClinical Solutions, a leader in clinical research software solutions, today announced a new partnership which will provide RealTime’s network of clinical research sites with expanded access to IgniteData’s Archer platform to securely and efficiently transfer clinical data. Archer is the only platform built from the ground up solely to solve for long-standing data tr

WALTHAM, Mass.--(BUSINESS WIRE)-- #ACR2026--Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026.

WHITMORE LAKE, Mich. & SARASOTA, Fla.--(BUSINESS WIRE)--Trace Medical, a national leader in advanced respiratory rentals and biomedical services, announced that it has acquired a majority interest in LiViliti Health Products, Inc. The acquisition follows LiViliti receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Paptizer 360 classified as a Class II Respiratory Accessory Microbial Reduction Device for CPAP equipment. The majority acquisition builds upon the exi

TAMPA, Fla. & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, and Mantra™, a consumer health company developing single-serve, over the counter (OTC) oral gel products for everyday relief, today announced a commercial supply agreement for Mantra’s oral gel product platform. Catalent will provide formulation development, commercial manufacturing and pa

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American, Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2026. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2026 were $7.82 million compared to $7.83 million for the third quarter of fiscal 2025. Net Income The Company reported net income of $1.27 mil

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics Inc., a late-stage biopharmaceutical company developing a new class of therapeutics designed to treat eye diseases by repairing helical collagen, today announced it has submitted an investigational new drug application amendment to the U.S. Food and Drug Administration to study its lead candidate, ST-100 (vezocolmitide), in corneal wound healing. The planned proof-of-concept study would mark ST-100's first expansion beyond dry eye disease and co

BOCA RATON, Fla.--(BUSINESS WIRE)-- #LumbarDecompression--SurGenTec®, a privately held medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that it has entered into an exclusive license agreement with Allevion Medical for its patented Vantage™ spinal decompression technology. Under the terms of the agreement, SurGenTec® has secured exclusive rights to Allevion Medical's Vantage™, a fully disposable, sterile system designed to simplify and enhance minimally in

DENVER--(BUSINESS WIRE)-- #AI--Cleerly, a leader in advanced cardiovascular imaging analysis, and Clear Heart and Lung Imaging, a leader in outpatient imaging care, have taken a cardiac-capable mobile CT scanner across the southern United States to expand access to cardiovascular research and enable communities and clinics to participate in Cleerly's TRANSFORM Trial. From July through September 2026, the CT scanner traveled through Arizona, Louisiana, Georgia, and Florida, bringing cardiovascular ima

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ supersonic aircraft, today announced the completion of its first flight hardware manufactured under a production agreement with Italian engineering company Robby Moto Engineering S.R.L. ("RME"), marking an important milestone in the Company's continued development of its previously ann

LAUSANNE, Switzerland, WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Timeline (Amazentis SA), the Swiss life-sciences company that pioneered the healthy aging ingredient Urolithin A and its branded form Mitopure®, together with its U.S. subsidiary Timeline Longevity, Inc., announced today that the U.S. District Court for the District of Massachusetts has granted an ex parte temporary restraining order against the operators of a network of websites that impersonate Timeline’s official site, www.timeli

LAKELAND, Fla.--(BUSINESS WIRE)--As Publix celebrates National Seafood Month, the company continues its long-standing commitment to advancing sustainable seafood by donating nearly $100,000 to Sustainable Fisheries Partnership (SFP) in 2026 alone, bringing its total contribution to the organization to more than $1.2 million.Now in its 16th year, Publix’s collaboration with the nonprofit highlights the company’s environmental stewardship and responsible sourcing efforts. SFP works with the seafoo

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #Cordis--Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the SELUTION SLR SUSTANE™ PTA Drug-Eluting Balloon (SUSTANE DEB) achieved the highest reported 12-month primary patency in the SELUTION4SFA US pivotal trial at 90.3%. The results were presented during a Late-Breaking Clinical Trial session at VIVA 2026 by Jay Mathews, MD, MS, Director, Cardiac Catheterization Laboratory, PERT & Structural Heart at

MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced the appointment of Juan R. Sanchez-Ramos, M.D., Ph.D., to its Scientific Advisory Board. A neurologist and clinician-scientist whose career has spanned addiction, movement disorders, and neurodegenerative diseases, Dr. Sanchez-Ramos was an early leader in the clinical investigation of ibogaine and a scientific collaborator of DemeRx founder and CEO D

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.

MELBOURNE, Fla.--(BUSINESS WIRE)--Smart seating company Kalogon names former Meta, Magic Leap executive Marty Evans as its first chief technology officer.

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the U.S. launch of an accelerated gene-to-drug substance program for complex biologics, designed to help developers move bispecifics, multispecifics and other next-generation molecules from gene sequence to drug substance in 10 months. The program builds on Catalent's Rapid Antibody offering for t

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approxi

ANTALYA, Turkey & JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced it has been awarded a contract by Axiom Space, a leader in next-generation space infrastructure, to develop and deliver two Roll-Out Solar Array (ROSA) wings for Axiom Station’s second space station module. As previously announced, Redwire is also building the ROSA wings for Axiom Space’s first space station module. “We are excited an

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robu

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode. This confer

ORLANDO, Fla.--(BUSINESS WIRE)-- #MedicalDevices--Xenix Medical Announces FDA Clearance of NanoACTIV™ Surface Technology for Its Riva® Posterior Fixation System.

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, Inc., an agentic AI and real-world data company advancing oncology drug development and access, today announced its inclusion in TIME’s World’s Top HealthTech Companies 2026 in the AI & Data Analytics category. Produced in collaboration with Statista, the list recognizes 500 companies worldwide based on financial performance, reputation and online engagement. The recognition comes as Massive Bio expands its role as oncology data and AI infrast

CORAL SPRINGS, Fla.--(BUSINESS WIRE)--ACIC Equipment USA will join ACIC Pharmaceuticals at CPHI Milan 2026, bringing together ACIC's pharmaceutical expertise and global network of technology partners to showcase an integrated approach to pharmaceutical development, manufacturing and commercialization. From October 6–8, 2026, visitors to Stand 7G106 can meet both teams and discover how ACIC connects pharmaceutical expertise, advanced manufacturing technologies and specialized engineering to help

BOCA RATON, Fla. & COLUMBUS, Ohio--(BUSINESS WIRE)--The TECPR2 Research Foundation, a nonprofit organization established to advance research and development of a treatment for patients with TECPR2, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to advance an AAV gene therapy for patients with TECPR2, an ultra-rare neurodegenerative genetic disease. Under the partners

GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp. today announced that its Co-Founder & Chief Scientific Officer, Dr. David Vaillancourt, will serve as a key scientific leader in a $22 million National Institutes of Health grant supporting the University of Florida-led Alzheimer’s Disease Research Center (1Florida ADRC). The award positions Florida among a select national network of only 37 ADRCs in the United States and the only one located in the state, expanding the region's role in a

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve). Moreover, Summit and AstraZeneca intend to evaluat

MIAMI & NUREMBERG, Germany--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer risk detection technology, today announced the commercial launch of DermaSensor in Germany through a distribution agreement with ContraCare GmbH. The launch represents a significant milestone in DermaSensor’s international expansion following its recent Class IIb CE Mark under the European Union Medical Device Regulation (MDR) and collaboration with the National Health Service (NHS) in the United K

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts and clinical partners for interoperability with the company's new radiotherapy system, Accela. Unveiled at the annual ASTRO conference, Accela is the first software-driven delivery system engineered for NeoArc (Dynamic Modulated Arc Therapy, DMAT), a new treatment technique that accelerates how radia

MIAMI-DADE, Fla. & BROWARD, Fla. & PALM BEACH, Fla. & DUVAL, Fla. & HILLSBOROUGH, Fla.--(BUSINESS WIRE)--Little more than half (52%) of respondents, and less than half (43%) of those aged 30-39, are very aware that breast cancer diagnoses have been rising among younger patients, according to a poll of more than 1,000 Florida-based women. Findings show 32% are somewhat aware of this increase, and 17% are either not very aware (11%) or not at all aware (6%). Conducted by the TopLine MD Alliance —

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, will bring next-generation innovations for next-level confidence to the ASTRO 2026 Annual Meeting, beginning Sunday, September 27, in Boston. At Booth 915, attendees will get a first look at new solutions for radiation therapy quality assurance (QA), alongside dedicated programming on smarter QA workflows and one of oncology's fastest-growing areas: radiopharmaceutical therapy.An Exclusive Look: A New Way to See Machine Hea

EDISON, N.J.--(BUSINESS WIRE)-- #CollaborativeSurgicalIntelligence--Redefine Surgery, a medical technology company building physical AI for surgery, today announced the closing of an oversubscribed pre-seed financing round, bringing total capital raised to $10 million. Backed predominantly by surgeon investors, the financing will support continued development of the company’s surgical intelligence platform as it advances toward commercialization. The financing announcement follows Wednesday’s announcement by Catalyst OrthoScience

MIAMI & COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading full-stack quantum platform and foundry, today announced a contract with Florida International University (FIU), Miami’s top ranked state university. Under the agreement, IonQ will deliver its Superion 256-qubit trapped-ion quantum computer for installation at FIU.This contract establishes FIU as IonQ’s flagship academic partner in Florida, creating a central hub for quantum research and education across the regio

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Together with more than 20,000 Associates nationwide, AutoNation, Inc. (NYSE:AN) celebrates a decade of DRV PNK and more than $50 million raised and donated to drive out cancer. To commemorate these milestones, AutoNation announced an additional $1 million investment through 10 grants of $100,000 each to 10 longtime partners advancing cancer research and supporting patients, survivors, and caregivers. Over the past decade, DRV PNK has evolved into a defin

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience, Inc. ("Catalyst"), a private medical technology company elevating shoulder arthroplasty through surgeon-focused innovation, today announced it has become the founding partner for shoulder with Redefine Surgery. Building on Catalyst’s leadership in efficient, outcomes-focused shoulder replacement, the partnership expands Catalyst’s role in shaping how shoulder replacement is measured, optimized and continuously improved, unlocking new levels

TAMPA, Fla. & SAN FRANCISCO--(BUSINESS WIRE)--ApalyRx, the pharmacy technology platform that assesses every prescription in real time and routes it to its lowest-cost fulfillment channel on benefit, today announced a partnership with Vida Health, a leading digital health company delivering integrated, longitudinal cardiometabolic and behavioral health care. Together, ApalyRx and Vida Health are enabling self-funded employers to provide plan members with comprehensive clinical weight-loss care a

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Rx, a leading provider of long-term care, specialty, and infusion pharmacy solutions, has once again been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca's at-home flu vaccine service, available for the 2026-2027 flu season. This marks the second consecutive year Polaris Rx has earned this exclusive distinction. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home without a doc

CORAL SPRINGS, Fla.--(BUSINESS WIRE)--ACIC Equipment USA Inc. is pleased to announce the appointment of Patrice Pelletier as President. In this role, Patrice will lead ACIC Equipment's sales strategy and commercial execution across North America, while also driving the strategic development of a new US facility for the company. Patrice brings more than 20 years of executive leadership experience across industrial technology, infrastructure, and energy transition, with a track record of scaling

ORLANDO, Fla.--(BUSINESS WIRE)-- #InterbodyFusion--Xenix Medical Announces FDA Clearance of the Riva® Anchor Spinopelvic Fixation System with NanoACTIV™ Surface Technology

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured as part of the Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) which takes place October 23–27, 2026, in Madrid, Spain. The presentation will take place on Sunday, O

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #Cordis--Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved the SELUTION SLR™ (Sustained Limus Release) Drug-Eluting Balloon (DEB) for the treatment of coronary in-stent restenosis (ISR), marking a major milestone in expanding treatment options for one of the most complex challenges in interventional cardiology. Physicians now have immediate access to the

BOCA RATON, Fla.--(BUSINESS WIRE)--US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and build partnerships across the country's oncology sector. Massive Bio provides an AI-powered platform that connects cancer patients with suitable clinical trials. The company works with global pharmaceutical companies, hospitals and oncologists to identify patients who meet the often highly specific requirements

MIAMI & PHILADELPHIA--(BUSINESS WIRE)--OpenEvidence, the most widely used medical AI and clinical decision-making tool among U.S. physicians, and Penn Medicine today announced a global partnership to bring AI-powered clinical decision support to Penn Medicine's more than 10,000 clinicians across its seven-hospital U.S. health system. That clinical decision support will also extend to low and middle income countries through the Botswana-UPenn Partnership (BUP). Building on Penn Medicine’s deep c

AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2B395--A2 Biotherapeutics to Announce Findings from DENALI-1 Study of A2B395 at 2026 Cell Coast Conference

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing a new class of therapeutics designed to repair helical collagen for the treatment of eye diseases, today announced that Eric Schlumpf, President and CEO of Stuart Therapeutics, will participate in a fireside chat discussion at the Citizens Private Ophthalmology Summit on Thursday, September 17, 2026, at 2 p.m. EDT. The Summit will showcase innovation in ophthalmology with prese

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. As Summit previously announced on July 22, 2026, ivonescimab plus plat

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #KnowLpa--The Family Heart Foundation, a leading research, education and advocacy organization, today announced the publication of a new peer-reviewed study in JACC: Advances demonstrating how its FIND Lp(a)® Machine Learning Model can identify people with atherosclerotic cardiovascular disease (ASCVD) who are more likely to have high lipoprotein(a) — or Lp(a). The model has already been successfully deployed at five large U.S. healthcare systems participating in

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Perdoceo Education Corporation Signs Definitive Agreement to Acquire South University

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab is being presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. The HARMON

MIAMI & OTTAWA, Ontario--(BUSINESS WIRE)-- #Canada--OpenEvidence and the Medical Identification Number for Canada Corporation (MINC#NIMC) today announced a partnership to streamline physician verification for Canada and support continued free access for verified Canadian clinicians. Medical knowledge keeps accelerating, and clinicians do not have time to chase down answers across dozens of tabs and paywalls. This partnership reduces friction at the moment of sign-up by allowing Canadian physicians to ver

SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences, Inc. (“Belenos”), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced positive interim results from its ongoing randomized, double-blind, placebo-controlled Phase 1b study of BEL512, an investigational long-acting bispecific antibody targeting thymic stromal lymphopoietin (“TSLP”) and interleukin-13 (“IL-13”), in patients with mild-moderate asthma. Phase 1b Tr

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, Inc., a global leader in AI-driven precision oncology and clinical trial matching, and PrecisCa, an oncology practice support platform offering evidence-based treatment guidance, clinical trial matching, patient communications, and expert second opinions, today announced a strategic partnership to expand cancer patient access to clinical trials across the United States. Under the agreement, Massive Bio will provide concierge support, reporting, an

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that it has entered into a settlement agreement with Shoulder Innovations, Inc. (“Shoulder Innovations”) to resolve all pending patent litigation between the two companies. The agreement resolves the dispute in its entirety. The terms of the settlement agreement are confidential. “Inte

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the space company operating the world’s only commercial fleet of flight-ready Mach 2+ supersonic aircraft, and Vaya Defense & Space, Inc. (“Vaya”), a privately held developer of the patented Vortex-Hybrid rocket engine, today announced entering into a memorandum of understanding (MOU) to explore collaboration on supersonic captive-carry flight testing and air-launch

MIAMI--(BUSINESS WIRE)--Lotus Neuro, a clinical-stage biotechnology company pairing focused ultrasound with leading therapeutic modalities to treat focal neurologic disease, today announced its public launch. Spun out in December 2025 from Insightec, the global leader in incisionless focused ultrasound, Lotus Neuro is built on a clinically validated platform for precision modulation of the blood-brain barrier (BBB) and is dedicated to solving the delivery problem that has stalled decades of pro

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, announced today the close of a $4M Series B extension, including institutional and strategic investors, alongside the launch of a community investment round on Wefunder. This new community financing has already raised more than $1 million at the same terms as the $4M. This follows the company’s $16M Series B, closed in 2025, and brings the total investment in the company to $48 million. The commu

MIAMI--(BUSINESS WIRE)-- #Glaucoma--Heru announced the U.S. launch of the new PretestPro on its Heru Prime wearable platform. PretestPro runs four pretest exams in just 90 seconds.

ATLANTIC BEACH, Fla.--(BUSINESS WIRE)--nPhase launches nPhase.ai and its agentic SCE, turning raw clinical trial data into submission-ready CDISC outputs 4x faster with 80% fewer resources.

LAKE FOREST, Calif.--(BUSINESS WIRE)--SinglePass, Inc., developer of the SinglePass biopsy closure device, today announced the publication of a multicenter (Hoag Health System, Newport Beach and Irvine, California) retrospective clinical data study in the Journal of Vascular and Interventional Radiology (JVIR). Across 120 consecutive patients followed for 30 days, the SinglePass device achieved a 100% technical success rate with zero clinically significant bleeding events.1 Percutaneous biopsy

MONTPELLIER, France & MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will unveil new features for its Epione® robotic platform at the 2026 annual congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Copenhagen, Denmark, September 5–9, on Booth D39. The updated platform will feature new AI capabilities and compatibility with one of the latest-generation angiography systems from GE HealthCare enabling

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression. HARMONi-2 (AK112-303) is a single-region, multi-center Phase III study conducted in China

MIAMI--(BUSINESS WIRE)--Over 90 Segal Trials employees have joined CISCRP’s 8th Annual Medical Heroes Appreci-A-Thon, a two-week event combining physical activity and fundraising to recognize the clinical research participants and professionals who make medical progress possible. Running September 1 through September 15, the Appreci-A-Thon raises funds to support CISCRP’s work educating and empowering patients and the public about clinical research. Just two days into the challenge, Segal Trial

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ supersonic aircraft, today announced it has signed a memorandum of understanding (“MOU”) with The Bionetics Corporation (“Bionetics”) to integrate and process a series of pathfinder small payloads for missions aboard the Company’s F-104 aircraft. Under the MOU, Bionetics will work with

MIAMI--(BUSINESS WIRE)-- #DebtJustice--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will co-host a webinar, “Freedom from Debt: A Global Dialogue on Fiscal Space, Health, and Development,” on Thursday, September 3, 2026, at 10:00 AM EDT, virtually via Zoom. Register here. Sovereign debt has emerged as a defining challenge at the intersection of global finance, sustainable development, and public health. Across many low- and middle-income countries,

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ F-104 supersonic aircraft, announced it will participate in the September 12-13 AIRSHO at the Midland International Air & Space Port in Texas, showcasing its historic F-104 aircraft in both flight and static displays. For Starfighters, the event provides a unique opportunity to sho

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, today announced a major expansion of its U.S. commercial strategy through a series of strategic partnerships to accelerate adoption of its FDA cleared, handheld skin cancer detection device across primary care, enterprise healthcare, and federal healthcare systems. The Company's commercial expansion includes 1) an approved supplier relationship with Henry Schein, Inc., the world’s largest provide

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)-- #clinicalai--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company’s investor relations website: https://www.conmed.com/en/inv

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of Dave LeCause as senior commercial advisor. LeCause will lead the company's commercial strategy as Stuart advances its lead therapeutic candidate, ST-100 for dry eye disease. ST-100 is expected to begin Phase 3b clinical trials in the first quarter of 2027. LeCause joins Stu

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusi

TAMPA, Fla.--(BUSINESS WIRE)--Catalent has completed a significant debt refinancing transaction to support its future growth while reducing its annual interest expenses.

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In HARMONi, ivonescimab in combination with platinum-doublet chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mu

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #ClinicalResearch--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia.MapLight Therapeutics recently announced topline results from the multicenter Phase 2 study. Segal Trials is proud to have contributed to this important clinical development program and congratulates

MIAMI--(BUSINESS WIRE)-- #AI--Arcadia Capital, the premier strategic advisor and investment bank to leaders in the tech and tech services ecosystem, served as exclusive financial advisor to InformedDNA ("IDNA" or "the Company"), a portfolio company of Truehelm and QHP Capital, in the divestiture of its Genetic Testing Utilization Management ("GTUM") business unit to Zyter, a subsidiary of Infinite, a global technology company. The transaction marks the Company's continued investment in and focus on D

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, a leading provider of cellular-connected remote patient monitoring (RPM) solutions, today called on RPM vendors, healthcare providers, and industry partners to mobilize against provisions in the Centers for Medicare & Medicaid Services' (CMS) proposed Calendar Year 2027 Physician Fee Schedule (PFS) that could sharply curtail access to remote monitoring for millions of Medicare beneficiaries. The proposed rule, issued July 14, 2026, includes several

MINNETONKA, Minn. & REHOVOT, Israel & ORLANDO, Fla.--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS), a global leader in additive manufacturing solutions, and Limbitless Solutions, a nonprofit research facility at the University of Central Florida dedicated to empowering children through bionics, today announced the expansion of a 12-year collaboration that has already helped deliver hundreds of 3D-printed prosthetic devices to children across the United States and beyond. The expanded partnersh

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commerciali

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Wellvii today announced that its innovative BP Go blood pressure monitoring technology achieved FDA clearance, marking a significant milestone in the company’s mission to transform remote patient monitoring and connected healthcare. The BP Go is designed to simplify the blood pressure measurement by utilizing a convenient finger-based measurement approach, eliminating many of the challenges associated with traditional arm cuffs. The device is designed

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un

BOCA RATON, Fla.--(BUSINESS WIRE)-- #HealthcareInnovation--SurGenTec®, a developer of surgical technologies for spine and orthopedic procedures, today announced that it has been named to the 2026 Inc. 5000, the annual list of the fastest-growing private companies in America. The prestigious list recognizes companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2

HOLLYWOOD, Fla. & DALLAS--(BUSINESS WIRE)--DermCare Management, LLC (“DermCare”), a leader in specialized dermatology and cosmetic surgery practice-management services, and U.S. Dermatology Partners (“USDP”), a leading dermatology practice, today announced the completion of a strategic transaction that creates one of the largest dermatology groups in the U.S., spanning 12 states. The transaction unites two clinically focused organizations with aligned missions to expand access to high-quality d

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). Thi

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Com

SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences Announces Positive CRSwNP Results

TAMPA, Fla.--(BUSINESS WIRE)--American Ocean Minerals Corporation ("AOMC" or the "Company") today announced that Paul Warmé has been appointed Chief Financial Officer. Through its previously announced merger with Odyssey Marine Exploration (NASDAQ: OMEX), AOMC is establishing a U.S.-based global supply chain for critical minerals and rare earth elements sourced from deep-sea polymetallic nodules, and Warmé’s appointment further strengthens the executive leadership team as the Company advances t

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisition by Merck; and Bill Warren, former Global Head of Antigen Design at Sanofi Vaccines, as independent members of ILiAD’s Board of Directors. T

CLEARWATER, Fla.--(BUSINESS WIRE)--PriceMDs and Leaf Health today announced the integration of PriceMDs’ API into LeafIQ, Leaf Health’s pharmacy analytics and reporting platform. The integration enables brokers and third-party administrators to evaluate applicable SourceDirectRx pricing and initiate clinical referrals while analyzing pharmacy spend and specialty medication exposure. Within LeafIQ, users can compare a plan’s current medication cost with available SourceDirectRx pricing without l

GAITHERSBURG, Md.--(BUSINESS WIRE)--Silvec Biologics Inc., a Maryland-based agricultural biotechnology company, is pleased to announce that its novel RNA-based therapy delivery product is now registered for unconditional commercial use under the U.S. Environmental Protection Agency’s (EPA) Federal Insecticide, Fungicide and Rodenticide Act. The product is based on a naturally non-transmitted version of the citrus tristeza virus that is already found in most Florida citrus trees that has been re

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approxim

JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Space Microgravity Development LLC (SpaceMD), a wholly owned subsidiary of Redwire Corporation (NYSE:RDW) and venture company focused on leveraging the microgravity environment to create dynamic innovations, announced today that it has signed a contract for a Starfall mission. Starfall is SpaceX’s new spacecraft that enables affordable, routine access to a microgravity environment and provides unique opportunities for on-orbit manufacturing, scientific resea

TULSA, Okla.--(BUSINESS WIRE)--Four startups headquartered in Colorado, Florida and Texas have been selected as winners of the 2026 Rose Rock Bridge Showcase. Austere Environmental, BiaTech, BigMachine AI and Intellicess will receive a share of $400,000 in non-dilutive funding and establish a presence in Tulsa to pilot and advance their technologies over the next year. The winning startups were selected from a pool of 85 highly qualified applicants. Collectively, they have already raised over $

MIAMI & NASHVILLE, Tenn.--(BUSINESS WIRE)-- #Oncology--OpenEvidence, the most widely used AI-powered medical search and clinical decision-support platform, and OneOncology, a physician-led national platform empowering independent medical specialty practices, today announced a partnership to embed OpenEvidence into certain clinical applications used across OneOncology’s platform to enable physicians to use OpenEvidence for clinical evidence retrieval, reference and research. The integration is designed to m

NEW YORK & MIAMI--(BUSINESS WIRE)-- #OpenEvidence--Springer Nature and OpenEvidence today announced a subscription agreement that brings peer-reviewed content from Springer Nature into OpenEvidence, where physicians can retrieve and cite it during patient care. This agreement took effect August 4 and forms part of Springer Nature’s community led ARC3 framework. Clinicians and healthcare professionals need quick and easy access to the very latest trusted insights to help inform their decisions. Today's announce

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class investigational bispecific antibody ivonescimab, into urothelial carcinoma, or bladder cancer, with the initiation of the global, multi-regional Phase II/III HARMONi-GU1 trial. Summit is starting a randomized Phase II/III clinical study, HARMONi-GU1, to evaluate ivonescimab plus the antibody-drug co

LAKELAND, Fla.--(BUSINESS WIRE)--Publix’s sales for the three months ended June 27, 2026 were $15.7 billion, a 1% increase from $15.6 billion in 2025. Publix’s sales for the six months ended June 27, 2026 were $31.9 billion, a 1.5% increase from $31.4 billion in 2025. The increase in sales for the three and six months ended June 27, 2026 compared to the three and six months ended June 28, 2025 was lower due to the impact of the Medicare maximum fair price (MFP) change effective January 1, 2026

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #ASPC2026--The Family Heart Foundation, a leading research, education and advocacy organization, today announced that Founder and Chief Executive Officer Katherine Wilemon has been named the 2026 Honorary Fellow Awardee by the American Society for Preventive Cardiology (ASPC), one of the nation's leading professional societies dedicated to advancing cardiovascular disease prevention. The award was presented during the ASPC 2026 Congress on Cardiovascular Disease Pre

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are enc

FORT WORTH, Texas--(BUSINESS WIRE)--EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination

KISSIMMEE, Fla.--(BUSINESS WIRE)-- #BattlefieldMedicine--PVP Labs, a clinical-stage biotechnology company advancing peptide-based therapeutics, today announced that research on Taphalgin® (Lumekefamide) has been selected for oral presentation at the 2026 Military Health System Research Symposium (MHSRS), a premier scientific forum focused on the unique medical needs of deployed Warfighters.Joseph Stauffer, D.O., MBA, FAPCR, Chief Medical Officer of PVP Labs, will present the company's research on Taphalgin as a promis

ORLANDO, Fla.--(BUSINESS WIRE)--Jackson PharmacyPros™, a pharmacy-exclusive staffing agency and workforce solutions provider, has been named to RXinsider's 2026 Pharmacy500, an annual recognition honoring the top pharmacy operations, supply chain businesses and associations that have made a significant impact on dispensing pharmacies across the United States over the past year. The 2026 listmakers are shaping the future of pharmacy through operational excellence, innovation and exceptional pati

LAKELAND, Fla.--(BUSINESS WIRE)--Eligible Medicare Plan D beneficiaries can have qualifying GLP-1 prescriptions filled at a Publix Pharmacy as part of the Medicare GLP-1 Bridge program. On July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge program, a new initiative designed to expand access to innovative GLP-1 drugs for weight management. The program will remain available through Dec. 31, 2027. Covered Prescriptions The GLP-1 drugs currently availa

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.0% on an organic cons

BOCA RATON, Fla. & CHARLOTTE, N.C. & ATLANTA--(BUSINESS WIRE)--Massive Bio, Inc., a leader in AI-enabled oncology clinical trial matching and patient navigation, and QC Healthcare, LLC, a nationwide company focused on telehealth, clinical research, pharmacy services, artificial intelligence, healthcare analytics, and population health, today announced a strategic collaboration to fundamentally reshape how cancer patients access clinical trials, coordinated care, and telehealth support throughou

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.

GAINESVILLE, Fla.--(BUSINESS WIRE)--Kiddom and the University of Florida Lastinger Center announced a research partnership studying if and how embedding professional learning at a teacher's precise point-of-need impacts instruction and student outcomes in middle school math.Kiddom built Florida's B.E.S.T.-aligned math curriculum to give teachers their core instructional materials, assessments, and insights in one coherent system. This partnership goes further, weaving Lastinger Center's instruct

ST. AUGUSTINE, Fla.--(BUSINESS WIRE)-- #MBC--Greenspace Health, a leader in Measurement-Based Care (MBC) technology for behavioral health, has launched Momentum, a new industry publication created to help behavioral health leaders navigate the growing shift toward outcomes-focused, value-based care. Featuring research, real-world case studies and practical implementation strategies, Momentum provides evidence-informed insights into the clinical, operational and economic impact of Measurement-Based Car

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin American Study Group on Lymphoproliferative Disorders (GELL), one of the most influential scientific and academic networks dedicated to lymphomas and hematologic malignancies in Latin America, today announced a strategic partnership focused on advancing clinical research, physician education, and innovation throu

PENSACOLA, Fla.--(BUSINESS WIRE)--Sugar Sands Publishing LLC today announced the formal constitution of the independent Cognitive Mode Operating System Standards Board (CMOS-SB) and launch of a governance framework for how AI systems interact with human emotion and cognition. THE GOVERNANCE GAP AI systems are increasingly being used in enterprise, health care, education and public infrastructure, where they can read emotional cues, respond to cognitive patterns and influence how people relate t

BOCA RATON, Fla.--(BUSINESS WIRE)-- #FDAClearance--SurGenTec®, a medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ION-L™ navigation instruments for use with the ION-L™ Lumbar Facet Fixation System. The system is engineered for compatibility with Medtronic's StealthStation™ navigation platform, enabling enhanced precision during posterior lumbar facet fusion proced

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress. “The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningf

TAMPA, Fla.--(BUSINESS WIRE)-- #biotech--Thyora Therapeutics today emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry, with a mission to accelerate clinical translation and create therapies for high-unmet medical needs. Founded on breakthrough discoveries published today in Science by scientists at Moffitt Cancer Center, the company is advancing an integrated platform that combines novel covalent chemistry with AI-enabled chemoproteomics to unlock a new generatio

MIAMI & LOS ANGELES--(BUSINESS WIRE)-- #ClinicalAI--The Los Angeles County Department of Public Health (DPH) and OpenEvidence, an AI-powered clinical decision support platform, today announced a collaboration to help physicians quickly find official LA County Public Health resources when searching for clinical information. Under this new partnership, when physicians in LA County search the platform for selected public health topics, OpenEvidence will display related LA-specific messages from Public Health. T

BOCA GRANDE, Fla.--(BUSINESS WIRE)--Avanti Capital establishes The Foundation in the U.S., advancing a multigenerational philanthropic legacy focused on research, education and impact.

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne